Alexander Drilon, MD, on Advanced Metastatic ROS1-Positive NSCLC: Zidesamtinib in TKI-Naive Patients

Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, presents efficacy and safety data from a phase II cohort of the ARROS-1 trial, which included patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who were naive to tyrosine kinase inhibitor (TKI) therapy (Abstract PL03.06).